In today’s briefing:
- Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: Double Impacts for Some Names
- Under The Lens of Disruption: Zoetis – VetKiosk
- Shandong Weigao Group Medical Polymer Co (1066.HK) – 2023 Full-Year Results Could Be Ugly
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: Double Impacts for Some Names
- The ChiNext Index represents the performance of the 100 largest and most liquid A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.
- The ChiNext 50 index is a subset of the ChiNext Index and it consists of the top 50 names in the ChiNext index with the highest daily average turnover.
- In this insight, we take a look at the names leading the race to become ADDs and DELs in the June 2024 index rebal event.
Under The Lens of Disruption: Zoetis – VetKiosk
- Honestly, I’m stunned I’m writing this. I did my research on Zoetis during June, July and August, and my conclusion seemed, funnily, conclusive.
- My suspicion was that Zoetis was as close to being a truly durable company as possible.
- Even though the object of this article does not claim otherwise, it does indeed reveal something I completely overlooked. My conclusion was ultimately drawn from the following:
Shandong Weigao Group Medical Polymer Co (1066.HK) – 2023 Full-Year Results Could Be Ugly
- Due to centralized procurement and anti-corruption campaign in 23H2, negative YoY revenue growth in 2023 seems to be inevitable. We are not optimistic about Weigao’s performance turnaround in 2024.
- After new policy strictly prohibiting borrowing to purchase medical equipment in public hospitals was released, the investment logic of medical device sector changes, which would negatively affect Weigao’s outlook.
- Weigao feels like “living off its past gains”.Current valuation is reasonable not undervalued. There’s no need to rush to long this stock when downward trend in share price hasn’t reversed.